Register for our free email digests:
Latest From Ortho-McNeil-Janssen Pharmaceuticals Inc.
2014 saw some big settlements in personal injury suits involving Rx drugs, but it’s unclear whether this is a trend or just situation-specific decision-making, since fierce litigation continues for many other products.
Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.
DOTW looks at Astellas’ oncology ambitions plus its recent split with partner Ambit, as well as analysis of Shire’s buyout of Premacure, AbbVie’s out-license of an anti-interleukin-13 antibody to Receptos and the Merck/Luminex collaboration on a companion diagnostic for Alzheimer’s disease.
The Pharmacovigilance Risk Assessment Committee is assessing whether use of third- and fourth-generation combined oral contraceptives should be limited to women who cannot take other birth control pills; this is the ninth group of drugs PRAC has been asked to review.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- SpineGuard SA
- Senior Management
Pierre Jerome, CEO
Manuel Lanfossi, CFO
Stéphane Bette, CTO
- Contact Info
Phone: (33) 1 45 18 45 19
10, Cours Louis Lumière
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.